Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.

Autor:	Abelson D; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Barajas J; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Stuart L; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Kim D; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Marimuthu A; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Hu C; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Yamamoto B; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Ailor E; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Whaley KJ; Mapp Biopharmaceutical, Inc, San Diego, California, USA., Vu H; Integrated Biotherapeutics, Rockville, Maryland, USA., Agans KN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Borisevich V; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Deer DJ; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Dobias NS; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Woolsey C; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Prasad AN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Peel JE; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Lawrence WS; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Cross RW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Fenton KA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA., Zeitlin L; Mapp Biopharmaceutical, Inc, San Diego, California, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 Nov 13; Vol. 228 (Suppl 7), pp. S701-S711.
DOI:	10.1093/infdis/jiad278
Abstrakt:	Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186YTE, for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure. Competing Interests: Potential conflicts of interest. D. A., J. B., L. S., D. K., A. M., C. H., E. A., and B. Y. are employees of Mapp. L. Z. and K. W. are employees and owners of Mapp. H. V. is an employee of Integrated Biotherapeutics. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu